Acquired resistance to EGFR-TKIs such as gefitinib and erlotinib is a critical obstacle in the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.